Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $147.50

Vaxcyte, Inc. (NASDAQ:PCVX) has received an average rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $147.50.

A number of brokerages recently weighed in on PCVX. Bank of America lifted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Jefferies Financial Group boosted their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. BTIG Research raised their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC lifted their target price on Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Mizuho increased their price target on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th.

Insider Buying and Selling

In related news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Elvia Cowan sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,081,455. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,000 shares of company stock valued at $6,508,130. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently added to or reduced their stakes in PCVX. Darwin Global Management Ltd. raised its stake in shares of Vaxcyte by 374.3% during the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after purchasing an additional 2,170,845 shares during the period. Vanguard Group Inc. raised its position in Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after acquiring an additional 1,284,883 shares during the period. Capital Research Global Investors raised its position in Vaxcyte by 20.4% in the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares during the period. Janus Henderson Group PLC boosted its stake in Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after acquiring an additional 692,492 shares during the last quarter. Finally, Avoro Capital Advisors LLC bought a new position in shares of Vaxcyte during the 1st quarter valued at approximately $39,278,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Trading Up 1.0 %

Shares of PCVX opened at $114.27 on Friday. The stock’s 50-day moving average price is $92.84 and its two-hundred day moving average price is $78.19. Vaxcyte has a 12 month low of $44.20 and a 12 month high of $121.06. The company has a market capitalization of $12.75 billion, a PE ratio of -26.70 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same period last year, the business earned ($0.70) earnings per share. Equities research analysts predict that Vaxcyte will post -4.33 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.